YEMI ONAKUNLE: My work helping to lead new business development efforts at Selexis continues to challenge and inspire me. I value my background in both business and science and I firmly believe that it’s been instrumental to my success. Not only am I able to intimately understand a company’s protein expression challenges and accurately communicate Selexis’ value proposition, but I can also structure partner relationships in ways that make sense for all parties. With that, I am so proud that we’ve bolstered our presence in the United States in two critical life sciences hubs with professionals whose careers also intersect at the corner of business and science. Today, I am happy to welcome two new business development colleagues, Jessica Bosc, our director of business development and licensing based in Boston, and Samuel Rubin, our manager of business development and licensing based in San Francisco. Though I’ve maintained close contact with partners in these locations, nothing replaces consistent opportunities for face-to-face meetings and networking. I spoke with Jessican and Sam recently about their experience and decision to join Selexis.
JESSICA BOSC: “I’ve been in the life sciences industry and in the Boston area for 15 years now and I’m looking forward to working with you (Yemi) to continue your great work ensuring Selexis’ visibility here. I gained hands-on cell line development and early process development experience at different biotechnology companies before moving to new business development roles several years ago. I have a solid understanding of the science so I can accurately convey the value of Selexis’ technology, while my business development background is helpful in always having an eye toward where companies are headed next with the creation of drug substance and product. Selexis has been industry leading in mammalian cell expression technologies for years now and has a strong reputation for its innovative offerings. You can get high expression of IgGs but there are all sorts of protein platforms out there. Selexis technology has been used to get high expression levels on some exciting new proteins so consistently fast. We have a lot of tools in the toolbox. There is a true scientific partnership with the client. I’m excited to work with this technology and ensure my customers understand the competitive advantage it will bring to their programs. Exploring the technology more deeply and talking with the team further drove home my decision to join Selexis.”
SAMUEL RUBIN: “My new role at Selexis aligns so closely with what I was looking for in my next role, which was a marriage between business and science. I have a Bachelor’s degree in biomedical engineering and a Master’s degree in technical entrepreneurship and management. Over the past several years I was a technical assistant and in research and development focused on cell and tissue engineering and bioprocess engineering, which I think will be hugely beneficial to my new role. Prior to joining Selexis I was on the business development side with Life Science Nation where I focused on connecting companies in the biotech, medtech, diagnostic and related industries with the right investors. In my next role, I was really looking for a sense of purpose and I believe I’ve found that with Selexis.”
BOSC: “When I’m not working, I am very active in Women In Bio. I’m the president-elect of the organization currently and look forward to being named president in 2020. I’ve been heavily involved for several years now and I feel strongly that it’s important for women to support each other. For downtime, I love spending time with my friends, family and two dogs – whether on walks or spending time at the beach or seeing live music.”
RUBIN: “Outside of work, I love playing all sports and am a big Boston sports fan. I also love reading and cooking. I’m excited to be in San Francisco and I’m looking forward to exploring all that Northern California has to offer.”
ONAKUNLE: Jessica and Sam have the tenacity we were looking for in new business development colleagues. But, most importantly, they have a passion for making a difference in the lives of underserved patients. Selexis and my team are very fortunate to benefit from their passion for science and business acumen and we’re confident they’ll make great strides in the active biotechnology communities of Boston and San Francisco.